摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

lasofoxifene

中文名称
——
中文别名
——
英文名称
lasofoxifene
英文别名
cis-6-phenyl-5-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol;cis-6-5-[4-(2-pyrrolidin-1-yl-ethoxy)phenyl]-5,6,7,8-tetrahydronaphthaIene-2-ol;6-phenyl-5-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol
lasofoxifene化学式
CAS
——
化学式
C28H31NO2
mdl
——
分子量
413.56
InChiKey
GXESHMAMLJKROZ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    6.1
  • 重原子数:
    31
  • 可旋转键数:
    6
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.36
  • 拓扑面积:
    32.7
  • 氢给体数:
    1
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    lasofoxifene盐酸 作用下, 以 1,4-二氧六环 为溶剂, 生成 lasofoxifene hydrochloride
    参考文献:
    名称:
    Pharmaceutical composition and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and an estrogen agonist/antagonist
    摘要:
    本发明涉及制药组合物和治疗方法,包括向需要的患者施用2-烷基亚甲基-19-去氢维生素D衍生物和雌激素激动剂/拮抗剂的组合物或其药学上可接受的盐或前药。特别是,本发明涉及制药组合物和治疗方法,包括向需要的患者施用2-亚甲基-19-去氢-20(S)-1α,25-二羟基维生素D3 和(-)-顺式-6-苯基-5-[4-(2-吡咯啉-1基-乙氧基)-苯基]-5,6,7,8-四氢萘-2-醇,或其药学上可接受的盐或前药。
    公开号:
    US20050070512A1
  • 作为产物:
    描述:
    cis-1-{2-[4-(6-methoxy-2-phenyl-1,2,3,4-tetrahydronaphthalene-1-yl)phenoxy]ethyl}pyrrolidine 在 三溴化硼 作用下, 以 二氯甲烷 为溶剂, 反应 3.0h, 以74%的产率得到lasofoxifene
    参考文献:
    名称:
    Pharmaceutical composition and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and an estrogen agonist/antagonist
    摘要:
    本发明涉及制药组合物和治疗方法,包括向需要的患者施用2-烷基亚甲基-19-去氢维生素D衍生物和雌激素激动剂/拮抗剂的组合物或其药学上可接受的盐或前药。特别是,本发明涉及制药组合物和治疗方法,包括向需要的患者施用2-亚甲基-19-去氢-20(S)-1α,25-二羟基维生素D3 和(-)-顺式-6-苯基-5-[4-(2-吡咯啉-1基-乙氧基)-苯基]-5,6,7,8-四氢萘-2-醇,或其药学上可接受的盐或前药。
    公开号:
    US20050070512A1
点击查看最新优质反应信息

文献信息

  • Dibenzyl Amine Compounds and Derivatives
    申请人:Chang George
    公开号:US20070213371A1
    公开(公告)日:2007-09-13
    Dibenzyl amine compounds and derivatives, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.
    二苯基胺化合物及其衍生物,含有这种化合物的药物组合物以及使用这种化合物提高某些血浆脂质水平,包括高密度脂蛋白胆固醇,并降低其他一些血浆脂质水平,如低密度脂蛋白胆固醇和甘油三酯,并据此治疗由高密度脂蛋白胆固醇水平低和/或低密度脂蛋白胆固醇和甘油三酯水平高加重的疾病,如动脉粥样硬化和心血管疾病在某些哺乳动物,包括人类。
  • [EN] NOVEL COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS
    申请人:PFIZER LTD
    公开号:WO2009144632A1
    公开(公告)日:2009-12-03
    The present invention relates to a class of substituted purine compounds of formula (I), uses thereof, processes for the preparation thereof and compositions containing said compounds. These compounds have utility in a variety of therapeutic areas including sexual dysfunction.(I).
    本发明涉及一类取代嘌呤化合物的公式(I),其用途、制备过程以及包含所述化合物的组合物。这些化合物在包括性功能障碍在内的多种治疗领域具有用途。
  • N-phenpropylcuclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase
    申请人:——
    公开号:US20030105132A1
    公开(公告)日:2003-06-05
    The invention relates to compounds of formula (I) for treating for example sexual dysfunction, wherein R 1 is optionally substituted C 1-6 alkyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, hydrogen, C 1-6 alkoxy, —NR 2 R 3 or —NR 4 SO 2 R 5 ; X is the linkage —(CH 2 ) n — or —(CH 2 ) q —O— (wherein Y is attached to the oxygen); wherein one or more hydrogen atoms in linkage X may be replaced independently by C 1-4 alkoxy; hydroxy; hydroxy(C 1-3 alkyl); C 3-7 cycloalkyl; carbocyclyl; heterocyclyl; or by C 1-4 alkyl optionally substituted by one or more fluoro or phenyl groups; n is 3, 4, 5, 6 or 7; and q is 2, 3, 4, 5 or 6; and Y is phenyl or pyridyl, each of which may be substituted; or two R 8 groups on adjacent carbon atoms together with the interconnecting carbon atoms may form a fused optionally substituted 5 - or 6 -membered carbocyclic or heterocyclyic ring. 1
    该发明涉及用于治疗性功能障碍的化合物(I)的公式,其中R1是可选择取代的C1-6烷基,可选择取代的碳环烷基,可选择取代的杂环烷基,氢,C1-6烷氧基,—NR2R3或—NR4SO2R5;X是连接基—(CH2)n—或—(CH2)q—O—(其中Y连接到氧原子);其中连接基X中的一个或多个氢原子可以独立地被C1-4烷氧基,羟基,羟基(C1-3烷基),C3-7环烷基,碳环烷基,杂环烷基或可选择取代的一个或多个氟或苯基的C1-4烷基替代;n为3、4、5、6或7;q为2、3、4、5或6;Y为苯基或吡啶基,每个基都可以被取代;或相邻碳原子上的两个R8基连同相互连接的碳原子可以形成一个可选择取代的5-或6-成员碳环或杂环环。
  • New indazole and indolone derivatives and their use pharmaceuticals
    申请人:Allerton Norfor Charlotte Moira
    公开号:US20050267096A1
    公开(公告)日:2005-12-01
    The present invention provides for compounds of formula (I), which are a class of dopamine agonists, more particularly a class of agonists that are selective for D3 over D2. These compounds are useful for the treatment and/or prevention of sexual dysfunction, for example female sexual dysfunction (FSD), in particular female sexual arousal disorder (FSAD), hypoactive sexual desire disorder (HSDD; lack of interest in sex), female orgasmic disorder (FOD; inability to achieve orgasm); and male sexual dysfunction, in particular male erectile dysfunction (MED). Male sexual dysfunction as referred to herein is meant to include ejaculatory disorders such as premature ejaculation, anorgasmia (inability to achieve orgasm) or desire disorders such as hypoactive sexual desire disorder (HSDD; lack of interest in sex). These compounds are also useful in treating neuropsychiatric disorders and neurodegenerative disorders.
    本发明提供了一类多巴胺激动剂的化合物,具体来说是一类选择性作用于D3而非D2的激动剂。这些化合物可用于治疗和/或预防性功能障碍,例如女性性功能障碍(FSD),特别是女性性唤醒障碍(FSAD),性欲不振障碍(HSDD;对性欲缺乏兴趣),女性性高潮障碍(FOD;无法达到高潮);以及男性性功能障碍,特别是男性勃起功能障碍(MED)。本文提到的男性性功能障碍包括射精障碍,如早泄,无法达到高潮的无性感(无法达到高潮)或性欲障碍,如性欲不振(HSDD;对性欲缺乏兴趣)。这些化合物还可用于治疗神经精神障碍和神经退行性疾病。
  • Pharmaceutically active compounds
    申请人:Calabrese Antony Andrew
    公开号:US20050176772A1
    公开(公告)日:2005-08-11
    The present invention relates to a class of melanocortin MCR4 agonists of general formula (I) wherein R 1 , R 2 , R 3 , R 4 and R 5 are as defined herein and especially to selective MCR4 agonist compounds, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes.
    本发明涉及一类通式(I)所示的黑素皮质素MCR4激动剂,其中R1、R2、R3、R4和R5如本文所定义,特别涉及选择性MCR4激动剂化合物,它们在医学上的应用,含有它们的组合物,用于它们制备的工艺以及用于这些工艺的中间体。
查看更多